Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
Since the release of the DESTINY-Breast04 (DB-04) trial findings in June 2022, the field of
pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The …
pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The …
Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer
M Chen, W Chen, D Liu, W Chen, K Shen, J Wu, L Zhu - Breast Cancer, 2022 - Springer
Background Human epidermal growth factor receptor 2 (HER2) low breast cancer was
considered as a distinct subtype different from HER2-zero breast cancer. Our study aimed to …
considered as a distinct subtype different from HER2-zero breast cancer. Our study aimed to …
Clinical, pathological complete response, and prognosis characteristics of HER2-low breast cancer in the neoadjuvant chemotherapy setting: a retrospective analysis
Y Shao, Y Yu, Z Luo, H Guan, F Zhu, Y He… - Annals of surgical …, 2022 - Springer
Background The present study was conducted to evaluate the clinical, pathological
response, and prognosis characteristics of human epidermal growth factor receptor 2 …
response, and prognosis characteristics of human epidermal growth factor receptor 2 …
Clinical Implications of Breast Cancer Intrinsic Subtypes
Abstract Estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast
cancers have different genomic architecture and show large-scale gene expression …
cancers have different genomic architecture and show large-scale gene expression …